Navigation Links
ViroPharma Announces Securities Repurchase Program
Date:3/9/2011

EXTON, Pa., March 9, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the company's Board of Directors has authorized the use of up to $150 million to repurchase shares of its common stock and/or its 2% Senior Convertible Notes due 2017.

Purchases may be made by means of open market transactions, block transactions, privately negotiated purchase transactions or other techniques from time to time, as determined by ViroPharma's management, and in accordance with the requirements of the Securities and Exchange Commission. As of December 31, 2010, ViroPharma had 78,141,491 shares of common stock issued and outstanding.

The sources of cash for this repurchase program are a combination of our cash, cash equivalents and short term investments on our balance sheet and our anticipated cash flows from operations.  ViroPharma produced cash flows of $194 million for the year 2010.

"We are committed to enhancing shareholder value through a variety of efforts," said Charles Rowland, ViroPharma's chief financial officer.  "To that end, today's announcement demonstrates our confidence in the future prospects of our existing business and our ongoing financial strength, which will continue to provide us the ability to pursue additional business development opportunities."

About ViroPharma IncorporatedViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze® (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vanc
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ViroPharma to Participate in Two March Healthcare Conferences
2. ViroPharma to Release 2010 Fourth Quarter and Full Year Financial Results on February 24, 2011
3. ViroPharma to Participate in Several Upcoming Healthcare Investor Conferences
4. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
5. ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010
6. ViroPharma to Present at the Jefferies 2010 Global Healthcare Conference
7. ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
8. ViroPharma To Participate in Two September Healthcare Investor Conferences
9. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
10. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
11. ViroPharma to Participate in Two June Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, ... Online, complimentary registration available at: http://bit.ly/1yStiU9 ... Archana Vidyasekar and Visionary Innovation Research Group ... wireless electricity, self-assembling materials, nanobots and flexible ... which will transform our lives in the ...
(Date:10/22/2014)... Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in ... drug for cancer, is designed for injection into solid ... oncology focus is on melanoma, breast cancer and cancers ... of PV-10 as a therapy for metastatic melanoma, and ... and psoriasis. This summer, the Company ...
(Date:10/22/2014)... , Oct. 22, 2014  Recently published clinical studies ... the already substantial database of evidence. This data has ... Stretta therapy for sufferers of refractory GERD. ... evidence supporting Stretta therapy as a safe and ... make Stretta therapy available to nearly 50 million Americans. ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2
... , , , ... CXM ) today announced that all patients enrolled in ... evaluation period and that it plans to provide detailed safety and ... (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO ) , , The Phase ...
... , , , RIDGEFIELD, ... (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran)(1) ... (ESC) Congress in Barcelona on Sunday, Aug. 30. The ... efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, ...
Cached Medicine Technology:Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 2Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 3Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 5Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 6Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 7Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 8Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 2Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 3Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 4Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 5Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 6Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 7
(Date:10/22/2014)... Steven Reinberg HealthDay Reporter , ... add weight and length may be showing a genetic propensity ... adults, certain genes have been linked to increased body fat, ... fat and lean muscle, the researchers said. At 1 ... By ages 2 and 3, however, these genes were linked ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... of conventional in vitro fertilization (IVF) -- the incubation of ... in a device inside the vagina, new research suggests. ... device, called an INVOcell, might sharply cut costs for pricey ... technology more accessible to those who don,t live near big-city ...
(Date:10/20/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... is the must-have source of thousands of facts, figures ... 72 countries and 68 medical sector forecast categories the ... you with global, regional and national views on the ... future outlook. , The report gives you data for ...
(Date:10/20/2014)... New York, NY (PRWEB) October 20, 2014 ... City based non-profit organization that helps New Yorkers ... lasting, positive changes toward health, housing, recovery and ... who have transformed the local community through their ... Managing Director, Marc Shapses , has been ...
(Date:10/20/2014)... 2014 Zereana Jess-Huff, a 34-year-old mother, corporate ... on a platform to think outside the bra. She doesn’t ... position to raise awareness about women’s other lady parts. , ... You say the color pink and everybody knows what you’re ... fact that it has not been won when it comes ...
Breaking Medicine News(10 mins):Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3
... ... web based clinical Label Approval System - LAS a unique workflow-based label approval management ... (PRWEB) ... launch of their new web based clinical Label Approval System - LAS a unique ...
... available in <A HREF=",http://chinese.eurekalert.org/zh/emb_releases/2010-04/aaoo-amb032510.php,">Chinese . ... very thin needles are used to stimulate specific ... responses, may be an effective treatment option for ... dysfunction (PVOD), according to new research in the ...
... Despite high levels of poverty and unemployment rates that ... families in rural Oregon tend to make less use ... with Oregon State University,s Family Policy Program. OSU ... Davis of the University of Minnesota, found that the ...
... one in four elderly Americans lacked the capacity to make their ... a study of 3,746 people to be published April 1 in ... had advance directives - including living wills or durable powers of ... the time, says lead author Maria Silveira, M.D., M.P.H., physician scientist ...
... those dying needed someone else to make decisions, research finds ... advance directives, such as a living will or a durable ... type of medical care that they,ve requested as they near ... The study also found that 30 percent of people required ...
... Breast ... leading a movement to tackle the post-medical world of breast cancer, one inspiring story at ... (PRWEB) ... had breast cancer to inspire them to transform their experience into something great. Her ...
Cached Medicine News:Health News:Almac to Improve Label Approval Process in Clinical Trials 2Health News:Almac to Improve Label Approval Process in Clinical Trials 3Health News:Acupuncture may be an effective treatment for post-viral infection loss of smell 2Health News:Despite much-higher poverty rates, rural Oregonians use less public assistance 2Health News:Despite much-higher poverty rates, rural Oregonians use less public assistance 3Health News:More than one-quarter of elderly patients lack decision-making capacity at death 2Health News:More than one-quarter of elderly patients lack decision-making capacity at death 3Health News:Advance Directives Help Assure End-of-Life Wishes Are Honored 2Health News:Advance Directives Help Assure End-of-Life Wishes Are Honored 3Health News:Breast Cancer Survivor Tackles the Missing Link: Inspiring Event Offers Women Real Life Advice to Thrive After Medical Treatment Ends 2Health News:Breast Cancer Survivor Tackles the Missing Link: Inspiring Event Offers Women Real Life Advice to Thrive After Medical Treatment Ends 3Health News:Breast Cancer Survivor Tackles the Missing Link: Inspiring Event Offers Women Real Life Advice to Thrive After Medical Treatment Ends 4
The Vitek 2 is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat bacte...
IDS Rapid Yeast Plus, a microbial identification system....
IDS Rapid NH, a microbial identification system....
The Cogent Microbial Luminescence System (MLS) is a superior Rapid microbial detection system for UHT product screening combining proven technology of ATP-bioluminescence with unsurpassed hardware in...
Medicine Products: